Mostrar el registro sencillo

dc.contributor.authorGallo-Terán, Jaimees_ES
dc.contributor.authorSalomón-Felechosa, Cristinaes_ES
dc.contributor.authorGonzález-Aguado, Rocíoes_ES
dc.contributor.authorOnecha, Estheres_ES
dc.contributor.authorFontalba, Anaes_ES
dc.contributor.authorDel Castillo, Ignacioes_ES
dc.contributor.authorMorales Angulo, Carmelo es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-05-08T12:12:14Z
dc.date.available2025-05-08T12:12:14Z
dc.date.issued2025es_ES
dc.identifier.issn0023-852Xes_ES
dc.identifier.issn1531-4995es_ES
dc.identifier.urihttps://hdl.handle.net/10902/36364
dc.description.abstractObjective: Mutations in the MTRNR1 gene of mitochondrial DNA are associated with non-syndromic hearing loss and increased susceptibility to aminoglycoside ototoxicity. The aim of our study was to determine the clinical characteristics of sensorineural hearing loss caused by the m.1555A>G mutation in MTRNR1. Methods: An observational retrospective study of the m.1555A>G mutation was conducted in patients with suspected hereditary bilateral sensorineural hearing loss in the Department of Otolaryngology of the Marqués de Valdecilla University Hospital (Cantabria, Spain) and in 100 controls with normal hearing. Results: The m.1555A>G mutation was found in 82 individuals from 20 different families and in none of the controls. Variable degrees of hearing loss were observed, ranging from normal hearing to profound deafness. Patients with a history of streptomycin administration exhibited significantly more pronounced hearing loss. The onset of hearing loss occurred from childhood to adulthood, with progression or stability over the years. No associated vestibular alterations or other clinical manifestations outside the ear were found. Two cochlear implant recipients showed significant improvement in speech comprehension. Conclusions: Patients with the m.1555A>G mutation in the MTRNR1 gene often develop bilateral, symmetric sensorineural hearing loss, predominantly affecting high frequencies, worsened by streptomycin administration. This mutation does not affect the vestibular function. The variability in the severity of hearing loss, the heterogeneity of phenotypic expression, and the presence of carrier individuals with normal hearing may indicate the existence of modifying factors, both environmental and genetic. Cochlear implantees showed a good response in terms of speech intelligibility. Genetic testing for this mutation is recommended in patients with a family history of hearing loss to prevent the use of aminoglycosides if the mutation is found.es_ES
dc.format.extent7 p.es_ES
dc.language.isoenges_ES
dc.publisherWiley-Blackwelles_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceThe Laryngoscope, 2025, 135(2), 901-907es_ES
dc.titleSensorineural hearing loss in patients with the m.1555A>G mutation in the MTRNR1 genees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1002/lary.31796es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1002/lary.31796es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International